GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sonoma Pharmaceuticals Inc (STU:O8Z) » Definitions » E10

Sonoma Pharmaceuticals (STU:O8Z) E10 : €-217.24 (As of Jun. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Sonoma Pharmaceuticals E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Sonoma Pharmaceuticals's adjusted earnings per share data for the three months ended in Jun. 2024 was €-1.301. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-217.24 for the trailing ten years ended in Jun. 2024.

During the past 3 years, the average E10 Growth Rate was 19.60% per year. During the past 5 years, the average E10 Growth Rate was 26.60% per year. During the past 10 years, the average E10 Growth Rate was 31.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Sonoma Pharmaceuticals was 38.40% per year. The lowest was 19.60% per year. And the median was 33.25% per year.

As of today (2024-09-21), Sonoma Pharmaceuticals's current stock price is €2.828. Sonoma Pharmaceuticals's E10 for the quarter that ended in Jun. 2024 was €-217.24. Sonoma Pharmaceuticals's Shiller PE Ratio of today is .


Sonoma Pharmaceuticals E10 Historical Data

The historical data trend for Sonoma Pharmaceuticals's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sonoma Pharmaceuticals E10 Chart

Sonoma Pharmaceuticals Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -607.38 -381.03 -279.86 -174.56 -237.14

Sonoma Pharmaceuticals Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -150.85 -134.91 -115.73 -237.14 -217.24

Competitive Comparison of Sonoma Pharmaceuticals's E10

For the Drug Manufacturers - Specialty & Generic subindustry, Sonoma Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sonoma Pharmaceuticals's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sonoma Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Sonoma Pharmaceuticals's Shiller PE Ratio falls into.



Sonoma Pharmaceuticals E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Sonoma Pharmaceuticals's adjusted earnings per share data for the three months ended in Jun. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Jun. 2024 (Change)*Current CPI (Jun. 2024)
=-1.301/132.5538*132.5538
=-1.301

Current CPI (Jun. 2024) = 132.5538.

Sonoma Pharmaceuticals Quarterly Data

per share eps CPI Adj_EPS
201409 -55.872 100.428 -73.745
201412 -503.632 99.070 -673.852
201503 -91.476 99.621 -121.716
201506 -123.493 100.684 -162.583
201509 -86.605 100.392 -114.351
201512 -158.630 99.792 -210.708
201603 -129.312 100.470 -170.605
201606 -97.722 101.688 -127.384
201609 -73.775 101.861 -96.005
201612 655.259 101.863 852.688
201703 -97.062 102.862 -125.079
201706 -131.364 103.349 -168.485
201709 -101.183 104.136 -128.795
201712 -111.033 104.011 -141.503
201803 -135.761 105.290 -170.916
201806 -85.429 106.317 -106.511
201809 -67.360 106.507 -83.833
201812 -41.665 105.998 -52.103
201903 -35.046 107.251 -43.314
201906 9.558 108.070 11.723
201909 -16.707 108.329 -20.443
201912 -12.960 108.420 -15.845
202003 -19.910 108.902 -24.234
202006 2.309 108.767 2.814
202009 1.019 109.815 1.230
202012 -5.261 109.897 -6.346
202103 -30.576 111.754 -36.267
202106 -8.632 114.631 -9.982
202109 -0.680 115.734 -0.779
202112 -5.487 117.630 -6.183
202203 -19.431 121.301 -21.234
202206 -5.487 125.017 -5.818
202209 -6.666 125.227 -7.056
202212 -11.706 125.222 -12.391
202303 -5.230 127.348 -5.444
202306 -5.353 128.729 -5.512
202309 -5.435 129.860 -5.548
202312 -1.467 129.419 -1.503
202403 -1.258 131.776 -1.265
202406 -1.301 132.554 -1.301

Add all the adjusted EPS together and divide 10 will get our e10.


Sonoma Pharmaceuticals  (STU:O8Z) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Sonoma Pharmaceuticals E10 Related Terms

Thank you for viewing the detailed overview of Sonoma Pharmaceuticals's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Sonoma Pharmaceuticals Business Description

Traded in Other Exchanges
Address
5445 Conestoga Court, Suite 150, Boulder, CO, USA, 80301
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, and other countries.

Sonoma Pharmaceuticals Headlines

No Headlines